David Pamies is a Postdoc at Department of Physiology on the Lausanne University. He got his master in Bioengineering and PhD in the Miguel Hernandez University. The focus of his PhD research was to elucidate the role of neuropathy target esterase (NTE) in the differentiation processes, using mouse embryonic stem cells in order to determine their role as a possible target in mammalian embryonic development toxicity and human NT2 cells to identify the role of NTE in the processes of differentiation to form the neuroectoderm. He also was working one year in the IHCP (European Commission). During his trainee period at the European Commission Joint Research Center (JRC), He was working in new 3D models to assess developmental neurotoxicity (DNT). Afterwards, he joined the Center for Alternatives to Animal Testing in January 2013, where he was working for 5 years, first as a postdoc and after as a research associated on developing and application of an iPSC-derived 3D human brain microphysiological system to study DNT, encephalitis, virus infection, Parkinson disease (PD) between others. Now, he is working on the use of new in vitro technologies to quantify adverse outcome pathways (AOPS) to help regulatory decision-making.